Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 20/20 | 0.58 |
| ▸ | ITGA4 | P13612 | 20/20 | 0.58 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.56 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27543603 | 0.86 | ITGB1 (0.69) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL6561608 | 0.86 | ITGB1 (0.69) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL5254597 | 0.79 | ITGB1 (0.60) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL14799578 | 0.79 | ITGB1 (0.56) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL6561292 | 0.79 | ITGB1 (0.56) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL5227929 | 0.79 | ITGB1 (0.64) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL2987945 | 0.77 | ITGB1 (0.54) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL2880989 | 0.77 | ITGB1 (0.74) | ITGB1ITGA4 | |
| SCHEMBL28833053 | 0.77 | ITGB1 (0.59) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL28833054 | 0.77 | ITGB1 (0.59) | ITGB1ITGA4ITGA2ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622867-B1 | N-(2-PHENYLETHYL)SULFAMIDE DERIVATIVES AS INTEGRIN ALPHA4 ANTAGONISTS | ALMIRALL LAB (ES) | 2007-09-19 | — | — | EP | disclosed |
| US-20070179183-A1 | N-(2-phenylethyl)sulfamide derivatives as integrin alpha4 antagonists | ALMIRALL, S.A. (ES) | 2007-08-02 | — | — | US | disclosed |
| EP-1622867-A1 | N-(2-PHENYLETHYL)SULFAMIDE DERIVATIVES AS INTEGRIN ALPHA4 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004099126-A1 | N-(2-PHENYLETHYL)SULFAMIDE DERIVATIVES AS INTEGRIN α4 ANTAGONISTS | ALMIRALL PRODESFARMA SA (ES) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179183-A1 | N-(2-phenylethyl)sulfamide derivatives as integrin alpha4 antagonists | ITGA4, ITGB4, ITGA2 | ITGB1 9/4885ITGA4 1/4885ITGA2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.